A recently published research study led by Drs. Sem Phan and Tianju Liu from the Department of Pathology reported new findings that could help scientists predict disease progression and suggest a new immunotherapy target for the treatment of IPF and other fibrotic lung diseases.
These findings uncovered a new role for the immune checkpoint marker (B7-H3) in lung fibrosis that can potentially serve as a novel target for immunotherapy to slow down or abort the progression of lung fibrosis in patients with IPF and other chronic lung fibrotic diseases. In addition, sB7H3 levels in the plasma could serve as a potential marker to predict how quickly the disease progresses in patients and assess responsiveness to therapy, allowing for more informed treatment decisions.
The laboratory of Dr. Chang Kim, recently published a high-impact study that elucidates the bone marrow niche and mechanisms by which innate lymphoid cells differentiate between those which remain in the bone marrow and those which emigrate to the rest of the body. Read more[...]
Findings offer clues to why some types of renal cell carcinoma respond to immunotherapy while others do not — it’s a scientific riddle tangled up in a complex web. How do you turn an immune cold cancer into one that responds to immunotherapy?
A series of sophisticated processes are required in the development of innate lymphoid cells (ILC) for them to reach maturity. The Kim laboratory discovered that basic leucine zipper ATF-like transcription factor (Batf) regulates the production of ILC progenitors in the bone marrow as well as the maintenance of ILCs in the periphery. These cells are strategically distributed in peripheral tissues to provide important innate immunity to fight pathogens such as pathogenic viruses and bacteria.
The study details research surrounding Respiratory Syncytial Virus (RSV) among infants.